Legacy Bridge’s Regeneron Pharmaceuticals REGN Stock Holding History

Legacy Bridge’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$3.09K	–	444
2025 Q4	$3.09K	Buy	+4	New	+$2.72K	﹤0.01%	392

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Legacy Bridge's REGN Position: Q1 2026 in Review

Legacy Bridge sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 4 shares — an estimated $3.09K sold.

Legacy Bridge first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $3.09K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Legacy Bridge reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Legacy Bridge sold 4 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.09K.
Legacy Bridge first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Legacy Bridge's Regeneron Pharmaceuticals position peaked at $3.09K in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Legacy Bridge's 13F filing for Q1 2026, filed 14 May 2026.